

ADDENDUM #2
STATE SUPPLEMENTAL REBATE/PREFERRED DRUG LIST (PDL)
LOUISIANA MEDICAID PROGRAM
BENEFITS AND SERVICES/PHARMACY PROGRAM
MEDICAL VENDOR ADMINISTRATION
BUREAU OF HEALTH SERVICES FINANCING
RFP # 305PUR-DHHRFP-PHARMACY-PDL-MVA
Proposal Due Date/Time: June 18, 2015 CT
Date: May 29, 2015

All additions and deletions are in red and underlined.

Document	Section	Change From:	Change To:
RFP	B. 3.d SR Reports and Documentation, Page 19	d. Track the effective dates of all Supplemental Rebate Agreements and provide the Department with a LAM Billing File Report, which includes manufacturer, labeler codes & names, national drug code (NDC), status, QA, value, calculation, start and end Dates, Price, document number & TOP\$ tier, no later than fifteen (15) calendar days after the end of each calendar month.	d. Track the effective dates of all Supplemental Rebate Agreements and provide the Department with a LAM Billing File Report, which includes manufacturer, labeler codes & names, national drug code (NDC), status, QA, value, calculation, start and end Dates, Price, document number & TOP\$ tier, no later than fifteen (15) calendar days after the end of each calendar month.
RFP	B. 3.e SR Reports and Documentation, Page 20	e. Produce a Monthly TOP\$ Contract Status Report which includes Mfg., Number, Document, Status, Start Date, End Date, and Products no later than fifteen (15) calendar days after the end of each calendar month.	e. Produce a Monthly TOP\$ Contract Status Report which includes Mfg., Number, Document, Status, Start Date, End Date, and Products no later than fifteen (15) calendar days after the end of each calendar month.
RFP	3 Supplemental Rebates, Item 3.1, Page 15	3.1 Maintain existing supplemental rebate agreements and negotiates new or renegotiates renewed supplemental rebate agreements with pharmaceutical manufacturers, as directed by the Department;	3.1 Maintain existing <u>or negotiate and execute new</u> supplemental rebate agreements <u>for drug products that are under contract at the time of award of the contract resulting from this RFP</u> and negotiate new or renegotiate renewed supplemental rebate agreements with pharmaceutical manufacturers, as directed by the Department;
RFP	10. Cost and Pricing Analysis, Page 3	10. Cost and Pricing Analysis	10. 12. Cost and Pricing Analysis